These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34675678)

  • 1. Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer.
    Witjes JA; Feikema AAH
    Cancer Manag Res; 2021; 13():7833-7839. PubMed ID: 34675678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
    Mak KS; Smith AB; Eidelman A; Clayman R; Niemierko A; Cheng JS; Matthews J; Drumm MR; Nielsen ME; Feldman AS; Lee RJ; Zietman AL; Chen RC; Shipley WU; Milowsky MI; Efstathiou JA
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1028-1036. PubMed ID: 27727064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.
    Qiu J; Zhang H; Xu D; Li L; Xu L; Jiang Y; Wen T; Lu S; Meng F; Feng L; Shu X
    J Oncol; 2022; 2022():7306198. PubMed ID: 35607328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    Su X; Dong C; Liao W; Liu W
    World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
    Gakis G; Efstathiou J; Lerner SP; Cookson MS; Keegan KA; Guru KA; Shipley WU; Heidenreich A; Schoenberg MP; Sagaloswky AI; Soloway MS; Stenzl A;
    Eur Urol; 2013 Jan; 63(1):45-57. PubMed ID: 22917985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
    Kim YJ; Byun SJ; Ahn H; Kim CS; Hong BS; Yoo S; Lee JL; Kim YS
    Oncotarget; 2017 Sep; 8(40):68996-69004. PubMed ID: 28978174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
    Kumar A; Cherry DR; Courtney PT; Nalawade V; Kotha N; Riviere PJ; Efstathiou J; McKay RR; Karim Kader A; Rose BS; Stewart TF
    Eur Urol Open Sci; 2021 Aug; 30():1-10. PubMed ID: 34337540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimodal therapy in muscle invasive bladder cancer management.
    Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
    Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.
    Veskimäe E; Neuzillet Y; Rouanne M; MacLennan S; Lam TBL; Yuan Y; Compérat E; Cowan NC; Gakis G; van der Heijden AG; Ribal MJ; Witjes JA; Lebrét T
    BJU Int; 2017 Jul; 120(1):12-24. PubMed ID: 28220653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
    Leow JJ; Bedke J; Chamie K; Collins JW; Daneshmand S; Grivas P; Heidenreich A; Messing EM; Royce TJ; Sankin AI; Schoenberg MP; Shipley WU; Villers A; Efstathiou JA; Bellmunt J; Stenzl A
    World J Urol; 2019 Jan; 37(1):61-83. PubMed ID: 30684034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.
    Fan X; He W; Huang J
    Transl Androl Urol; 2023 May; 12(5):802-808. PubMed ID: 37305635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
    Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.